Also known as IBI362 · LY3305677
A glucagon / GLP-1 dual agonist (oxyntomodulin-based) approved in China for weight management and diabetes — not yet FDA-approved.
Research refreshed
Mazdutide is a once-weekly glucagon / GLP-1 dual receptor agonist based on mammalian oxyntomodulin, the natural gut hormone that activates both receptors. Licensed by Innovent Biologics from Eli Lilly for China, it became the first GCG/GLP-1 dual agonist to reach the market when China’s NMPA approved it in 2025 — first for chronic weight management, then for type 2 diabetes. It is not FDA-approved; Eli Lilly retains rights outside China, where it remains investigational.
Mazdutide is built on oxyntomodulin, a naturally occurring gut hormone that — unusually — activates both the GLP-1 and glucagon receptors on its own. Engineering that dual activity into a stabilized, acylated, once-weekly peptide gives mazdutide the same glucagon/GLP-1 profile as survodutide, reached from a different molecular starting point.
Its development is notable for geography. Eli Lilly created the molecule (LY3305677) and licensed Chinese rights to Innovent Biologics (as IBI362) in 2019. In 2025 China’s NMPA approved it — first for long-term weight management, then for glycemic control in type 2 diabetes — making it the first glucagon/GLP-1 dual agonist approved anywhere. Late-stage Chinese trials (the GLORY program) reported weight reductions around 20% at higher doses. It is not FDA-approved, and outside China it remains investigational.
Dual agonism at the glucagon and GLP-1 receptors, modeled on oxyntomodulin — combining GLP-1 satiety and insulin effects with glucagon-driven energy expenditure.
Behind every vial of Mazdutide is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Mazdutide, specifically, is brought into being.
On paper, Mazdutide is C207H317N45O65 — about 4,476 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Mazdutide is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later. It also carries fatty-acid acylation, an extra step beyond a plain chain that adds both capability and cost.
The crude mixture — Mazdutide plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Mazdutide proves itself: identity confirmed by mass spectrometry against its ~4,476 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Mazdutide — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
An oxyntomodulin-based glucagon/GLP-1 dual agonist, acylated for once-weekly dosing and stabilized with unnatural residues, made by solid-phase synthesis. As with the other long acylated incretins, the fatty-acid step and deletion-sequence control over a long backbone define the quality picture.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Mazdutide, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Mazdutide is a once-weekly glucagon / GLP-1 dual receptor agonist based on oxyntomodulin, approved in China for weight management and type 2 diabetes and developed by Eli Lilly and Innovent.
No. It was approved in China (2025) for weight management and diabetes, but it is not FDA-approved; outside China it remains investigational. This page is a research and educational reference.
Both are glucagon / GLP-1 dual agonists, but mazdutide is based on the natural dual-acting hormone oxyntomodulin, while survodutide is a separate engineered peptide; they come from different developers.
Glucagon-receptor activation is studied for increasing energy expenditure and reducing liver fat, complementing GLP-1’s appetite and glucose effects.
Long-acting GLP-1 receptor agonist for glycemic control and weight management.
ViewThe once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
ViewDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.